Core Viewpoint - 华检医疗's stock price has surged nearly 13% in the afternoon, with a cumulative increase of over 130% in the past two weeks, reflecting strong market interest and strategic developments [1] Group 1: Strategic Developments - 华检医疗 has announced a strategic cooperation framework agreement with 华大共赢 to establish the 华检华大共赢创新药知识产权代币化基金 (IVD-BGI CoWin), which will invest in projects under the NewCo + RWA Web3 exchange ecosystem in Hong Kong, the US, or other overseas regions [1] - The fund is initiated by 华大基因, a leader in biotechnology, which brings years of investment experience and project resources in the innovative medical and pharmaceutical sectors [1] Group 2: Market Performance - Following the announcement of a dual primary listing in the US on July 14 and the launch of a new brand logo on July 30, 华检医疗's market capitalization has increased from 3.6 billion to nearly 8 billion HKD [1] - The company has positioned itself as a "new species" in the capital market through a combination of "stablecoins + medical RWA," indicating a significant shift in traditional medical finance [1] Group 3: Future Prospects - Applications for stablecoin licenses in New York and Hong Kong are ongoing, and the listing on Nasdaq has yet to occur, suggesting potential future growth and opportunities for 华检医疗 [1] - The strategic actions taken in July are likened to a surgical strike, utilizing Web3 technology to transform innovative pharmaceutical assets into "digital gold" on the blockchain [1]
港股异动｜华检医疗(01931)午后涨近13% 半个月内累计涨幅超1.3倍 七大战略行动助推公司市值翻倍